However, CRLs are also present in SCF complex E3 ligases, which are recruited by RUNX3 to degrade oncoproteins GLI1, and likely MYCN [30,35], so potential cancer treatments may require a more personalized approach. This evidence concerns the gene MYCN and cancer.